Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/34294
Title: | Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy |
Authors: | TANAKA, Denise Mayumi; OLIVEIRA, Luciano Fonseca Lemos de; MARIN-NETO, Jose Antonio; ROMANO, Minna Moreira Dias; CARVALHO, Eduardo Elias Vieira de; BARROS FILHO, Antonio Carlos Leite de; RIBEIRO, Fernando Fonseca Franca; CABEZA, Jorge Mejia; LOPES, Carla Duque; FABRICIO, Camila Godoy; KESPER, Norival; MOREIRA, Henrique Turin; WICHERT-ANA, Lauro; SCHMIDT, Andre; HIGUCHI, Maria de Lourdes; CUNHA-NETO, Edecio; SIMOES, Marcus Vinicius |
Citation: | JOURNAL OF NUCLEAR CARDIOLOGY, v.26, n.5, p.1569-1579, 2019 |
Abstract: | Background. Myocardial perfusion defects (MPD) due to coronary microvascular dysfunction is frequent in chronic Chagas cardiomyopathy (CCC) and may be involved with development of myocardial damage. We investigated whether MPD precedes left ventricular systolic dysfunction and tested the hypothesis that prolonged use of dipyridamole (DIPY) could reduce MPD in an experimental model of CCC in hamsters. Methods and results. We investigated female hamsters 6-months after T. cruzi infection (baseline condition) and control animals, divided into T. cruzi-infected animals treated with DIPY (CH 1 DIPY) or placebo (CH 1 PLB); and uninfected animals treated with DIPY (CO 1 DIPY) or placebo (CO 1 PLB). The animals were submitted to echocardiogram and rest SPECT-Sestamibi-Tc99m myocardial perfusion scintigraphy. Next, the animals were treated with DIPY (4 mg/kg bid, intraperitoneal) or saline for 30 days, and reevaluated with the same imaging methods. At baseline, the CH 1 PLB and CH 1 DIPY groups showed larger areas of perfusion defect (13.2 +/- 13.2% and 17.3 +/- 13.2%, respectively) compared with CO 1 PLB and CO 1 DIPY (3.8 +/- 2.2% e 3.5 +/- 2.7%, respectively), P <.05. After treatment, we observed: reduction of perfusion defects only in the CH 1 DIPY group (17.3 +/- 13.2% to 6.8 +/- 7.6%, P 5.001) and reduction of LVEF in CH 1 DIPY and CH 1 PLB groups (from 65.3 +/- 9.0% to 53.6 +/- 6.9% and from 69.3 +/- 5.0% to 54.4 +/- 8.6%, respectively, P <.001). Quantitative histology revealed greater extents of inflammation and interstitial fibrosis in both Chagas groups, compared with control group (P < .001), but no difference between Chagas groups (P >.05). Conclusions. The prolonged use of DIPY in this experimental model of CCC has reduced the rest myocardial perfusion defects, supporting the notion that those areas correspond to viable hypoperfused myocardium. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MCM Artigos e Materiais de Revistas Científicas - HC/ICHC Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - IMT Artigos e Materiais de Revistas Científicas - LIM/19 Artigos e Materiais de Revistas Científicas - LIM/49 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_TANAKA_Prolonged_dipyridamole_administration_reduces_myocardial_perfusion_defects_in_2019.PDF Restricted Access | publishedVersion (English) | 2.77 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.